Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: Long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors

Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: A systematic review and meta-analysis of 11 randomized controlled trials

14 p | 5 | 3

Gastrointestinal microbiota profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer

15 p | 5 | 3

Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer

8 p | 10 | 2

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma

9 p | 8 | 2

Gene alternation of cerebrospinal fuid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing

8 p | 5 | 2

Radiation pneumonitis after concurrent aumolertinib and thoracic radiotherapy in EGFR-mutant non-small cell lung cancer patients

10 p | 1 | 1

Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): Protocol of an open-label, singlearm phase II trial

7 p | 5 | 1

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers

7 p | 10 | 1

The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: A real-world observational study

11 p | 1 | 1